Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2004, Pages

  Singh, Bramah N ^a,b   Wadhani, Nitin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Amiodarone; Class III antiarrhythmic action; Proarrhythmia; Ranolazine; Torsadogenic potential; Transmural dispersion of repolarization

Indexed keywords

AMIODARONE; ANTIANGINA PECTORIS AGENT; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; DOFETILIDE; FATTY ACID; IBUTILIDE; ION CHANNEL; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; BRADYCARDIA; CARDIOVASCULAR RISK; DOG; DRUG MECHANISM; FATTY ACID OXIDATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER TOXICITY; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; QT PROLONGATION; REVIEW; THYROID DISEASE; TORSADE DES POINTES;

EID: 4944259885     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900107     Document Type: Review

References (64)

1. Singh BN. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: Particular reference to sotalol. Am J Cardiol 65(suppl): 3A-11A, 1990
2. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on class III actions. Am J Cardiol 84:11R-19R, 1990
3. Nattel S. New ideas about atrial fibrillation 50 years. Nature 415:219-226, 2002
4. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 350:1013-1022, 2004
5. Singh BN. When is QT prolongation anti-arrhythmic and when is it pro-arrhythmic? Am J Cardiol 63:867-869, 1989
6. Singh BN. Antiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 81(6A):3D-13D, 1998
7. Singh BN. Current antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 10:283-301, 1999
8. Selzer A, Wray HW. Quinidine syncope, paroxysmal ventricular fibrillations occurring during treatment of chronic atrial arrhythmias. Circulation 30:17-26, 1964
9. Johnson EA, Mckinnon JM. The differential effects of quinidine and pyrilamine on the myocardial action potential at various rates of stimulation. J Pharmacol Exp Ther 120:460-471, 1957
10. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation for the Q-T interval, and sudden death. Am Heart J 54:59-68, 1957
11. Dessertenne F. La tachycardie ventricular a deux foyers opposes variables. Arch Mal Coeur 59:263-272, 1966
12. The Cardiac Arrhythmia Suppression (CAST) Investigators. Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412, 1989
13. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39:675-687, 1970
14. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 39:657-667, 1970
15. Singh BN, Vaughan Williams EM. Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circulation Res 29:286-295, 1971
16. Singh BN, Vaughan Williams EM. A fourth class of antidysarrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 6:109-119, 1972
17. Singh BN. Pharmacological actions of certain drugs and hormones: Focus on studies of antiarrhythmic mechanisms. Doctor of Philosophy Thesis, Hertford College, University of Oxford (1971). Futura Publishing Co, Mt. Kisco, New York, 1991
18. Kaumann AJ, Olson C. Temporal relationship between long-lasting aftercontractions and action potentials in the cat papillary muscles. Science 163:293-299, 1968
19. Singh BN, Nademanee K. Control of cardiac arrhythmias by selective lengthening of cardiac repolarization: Theoretical considerations and clinical observations Am Heart J 109:421-430, 1985
20. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology and clinical pharmacology of amiodarone. Prog Cardiovsc Dis 106:249-280, 1992
21. Singh BN. Amiodarone: Historical development and pharmacologic profile. Am Heart J 106:788-796, 1983
22. Singh BN, Sarma JSM, Zhang ZH, Takanaka C. Controlling cardiac arrhythmias by lengthening repolarization: Rationale from experimental findings and clinical considerations. Ann NY Acad Sc 644:187-209, 1992
23. Bacaner MB. Treatment of ventricular fibrillation and other acute arrhythmias with bretylium tosylate. Am J Cardiol 21:530-538, 1968
24. Singh BN. Sotalol: Current status and expanding indications. J Cardiovasc Pharmacol Therapeut 4:49-65, 1999
25. Singh BN. Amiodrone: The expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 20:608-618, 1997
26. Antimisiaris M, Sarma JSM, Schoenbaum MP, et al. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: Significance for the control of sudden cardiac death. Am Heart J 128:884-891, 1994
27. Singh BN, Singh SN, Reda DJ, et al and SAFE-T Investigators. Antiarrhythmic therapy in maintaining stability of sinus rhythm in atrial fibrillation - Sotalol Amiodarone Atrial Fibrillation Efficacy Trial(SAFE-T). A Veterans Affairs Cooperative Study. Submitted N Engl J Med, 2004
28. Murray KT. Ibutilide. Circulation 97:493-497, 1998
29. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al for the Danish Investigations of Arrhythmia and Mortality on Dofetilide Study group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341:857-865, 1999
30. Nattel S, Liu L, St George D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 37(3):627-635, 1998
31. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride NE-10064), a class III antiarrhythmic agent. Cardiovas Drug Rev 15:137-156, 1997
32. Wei Sun, Sarma JSM, Singh BN. Electrophysiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative, in the rabbit heart: Comparison with amiodarone. Circulation 100:2276-2281, 1999
33. Singh BN, Mody FV, Lopez B, et al. Antiarrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization. Am J Cardiol 84:161R-173R, 1999
34. Camm AJ, Yap Guan Yee. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol 10:317-317, 1999
35. Hohnloser S, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: A review with special reference to torsades de pointes tachycardia. Ann Int Med 121:529-535, 1994
36. Anderson M, Al-Khatib, Roden DM, et al for an expert panel participating in a Duke Research Institute/American Heart Journal Expert Meeting on Repolarization Changes. Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient management. Am Heart J 144:769-781, 2002
37. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsades de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Cull Cardiol 12:806-817, 1983
38. Roden DM, Woosley RI, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: Implication for patient care. Am Heart J 111:1088-1093 1986
39. Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270:2590-2597, 1993
40. Napolitano C, Schwartz PJ, Brown AM, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 11:691-696, 2000
41. Van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic Amiodarone evokes no Torsades de Pointes arrhythmias despite QT lengthening in an animal model of acquired Long-QT Syndrome. Circulation 104:2722-2727, 2001
42. Antzelevitch C, Bellardinelli L, Wu Lin, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J. Cardiovac Pharmacol Therapeut 9(suppl 1):S65-S84, 2004
43. Sicouri S, Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cell (M cells) in the canine heart: Quinidine and dgitalis. J Cardiovasc Electrophysiol 4:48-58, 1993
44. Sun ZQ, Eddlestone GT, Antzelevitch C. Ionic mechanisms underlying the effects of sodium pentobarbital to diminish transmural dispersion of repolarization [abstr]. PACE 20:1116, 1997
45. Shimizu W, McMahon B, Antzelevitch C. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de pointes in models of acquired and congenital long QT syndromes. J Cardiovasc Electrophysiol 10:156-164, 1999
46. Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo. Torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 11:290-304, 2000
47. Amiodarone Trials Meta-Analysis Investigators. Effective of prophylactic amiodarone on mortality after myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials. Lancet 350:1417-1424, 1997
48. Hohnloser SH, Singh BN. Proarrhythmia with class III antiarrhythmic drugs: Definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications. J Cardiovasc Electrophysiol 6:920-936, 1995
49. Kodama I, Kamiya K, Toyama J. Cellular electrophysiology of amiodarone. Cardiovasc Res 35:L13-29, 1997
50. Singh BN. Electropharmacology of amiodarone. In: BN Singh (ed): Control of Cardiac Arrhythmias by Lengthening of Repolarization. Futura Publishing Co, Mt. Kisco, NY, pp 367-400, 1988
51. Papp Gy J, Nemeth M, Krassoi I, et al. Differential electrophysiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Cardiovasc Pharmacol Therapeut 1(4):287-296, 1996
52. Sicouri S, Moro S, Litovsky S, et al. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovac Electrophysiol 8:1269-1279, 1997
53. Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res 55:277-287, 1984
54. Takanaka C, Singh BN. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarization: Significance of slow channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol 15(1):213-221, 1990
55. Ohta M, Karaguezian HS, Mandel WJ, et al. Acute and chronic effects of amiodarone on delayed afterdepolarizations and triggered automaticity in rabbit ventricular muscle. Am Heart J:1214:289-298, 1987
56. Drouin E, Lande G, Charpentier F. Amiodarone reduces transmural heterogeneity of repolarization in the human heart. J Am Coll Cardiol 32(4):1063-1067, 1998
57. Cui G, Sen L, Sager PT, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 74:896-900, 1994
58. Glatter K, Young Y, Chatterjee K, et al. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients amiodarone therapy. Circulation 103:253-257, 2001
59. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94:1613-1621, 1996
60. Singh BN. Acute conversion of atrial flutter and fibrillation: Direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol 129:391-393, 1997
61. Pepine CJ, Wolff AA. A controlled trial with a novel antischemic agent, ranolazine, in chronic stable angina that is responsive to conventional anti-anginal agents. Ranolazine Study Group. Am J Cardiol 84:46-50, 1999
62. Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs 11:615-629, 2002
63. Stanley WC. Myocardial energy metabolism during ischemic and the mechanisms of metabolic therapies. J Cardiovasc Pharmacol Therapeut xx:xx-xx, 2004
64. Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: Review of evidence from clinical trials. J Cardiovasc Pharmacol Therapeut 9(suppl 1):S47-S64, 2004